T CELL SCIENCES COMPLETES OFFERINGT Cell Sciences Inc. last week said it completed a 2 million-share public offering at $6.50 a share, raising $13 million. TheCambridge, Mass.-based company now has 12.5 million sharesoutstanding. Underwriters Allen & Co. Inc. have an option topurchase 300,000 more shares to cover overallotments. T Cellstock (NASDAQ:TCEL) closed at $6.88, up 38 cents, on Friday.
MARROW-TECH ASKS TO EXTEND TRIALS
Marrow-Tech Inc. (NASDAQ:MAROA) of La Jolla, Calif., onThursday said it has asked the Food and Drug Administrationfor permission to extend clinical trials of its DermaGraft dermalskin replacement to patients with chronic venous skin ulcers.The company has been testing the product on victims of severeburns. Later trials will include other chronic skin ulcers, suchas those caused by diabetes, the company said.
(c) 1997 American Health Consultants. All rights reserved.